<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ksma</journal-id><journal-title-group><journal-title xml:lang="ru">Кубанский научный медицинский вестник</journal-title><trans-title-group xml:lang="en"><trans-title>Kuban Scientific Medical Bulletin</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1608-6228</issn><issn pub-type="epub">2541-9544</issn><publisher><publisher-name>Kuban State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25207/1608-6228-2018-25-2-108-114</article-id><article-id custom-type="elpub" pub-id-type="custom">ksma-1139</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ПАТОФИЗИОЛОГИЧЕСКОЕ ОБОСНОВАНИЕ ЭФФЕКТИВНОСТИ АНТИАНГИОГЕННОЙ ТЕРАПИИ ПРИ ОККЛЮЗИИ ВЕН СЕТЧАТКИ ПО ДАННЫМ КОГЕРЕНТНОЙ ТОМОГРАФИИ ГЛАЗА</article-title><trans-title-group xml:lang="en"><trans-title>PATHOPHYSIOLOGICAL REASONING OF THE EFFICIENCY OF ANTI-ANGIOGENIC THERAPY IN THE RETINAL VEIN OCCLUSION BY THE COHERENT EYE TOMOGRAPHY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Михайличенко</surname><given-names>В. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Mykhaylichenko</surname><given-names>V. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михайличенко Вячеслав Юрьевич, кафедра общей хирургии </p><p>бульвар Ленина, 5/7, Симферополь,295051</p></bio><bio xml:lang="en"><p>Department of GeneralSurgery </p><p>Lenina Boulevard, 5/7, Simferopol, Russia, 295051</p></bio><email xlink:type="simple">pancreas1978@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иващенко</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivashchenko</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра офтальмологии </p><p>, проспект Ленинский, 47, Донецк, ДНР, 83045</p></bio><bio xml:lang="en"><p>Department of Ophthalmology </p><p>Leninsky prospect 47, Donetsk, DNR, 83045</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самарин</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Samarin</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра анестезиологи и реаниматологии и скорой медицинской помощи </p><p>бульвар Ленина, 5/7, Симферополь, 295051</p></bio><bio xml:lang="en"><p>Lenina Boulevard, 5/7, Simferopol, Russia, 295051.</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волик</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Volik</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Отделение офтальмологии </p><p>, ул. Кирова, 9, Краснодар, Россия, 350063</p></bio><bio xml:lang="en"><p>Department of Ophthalmology</p><p> Kirova street 9, Krasnodar, Russia, 350063</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Медицинская академия им. С.И. Георгиевского ФГАОУ ВО «КФУ им. В.И. Вернадского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>1 S. I. Georgievskiy Medical Academy of V. I. Vernadskiy Crimean Federal University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Институт неотложной и восстановительной хирургии им. В.К. Гусака</institution><country>Украина</country></aff><aff xml:lang="en"><institution>V. K. Gusak Institute of Emergency and Reconstructive Surgery</institution><country>Ukraine</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Медицинская академия им. С.И. Георгиевского ФГАОУ ВО «КФУ им. В.И. Вернадского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>S. I. Georgievskiy Medical Academy of V. I. Vernadskiy Crimean Federal University, Department of Anesthesiology-resuscitaion and Emergency Medicine Simferopol</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Медицинская академия им. С.И. Георгиевского ФГАОУ ВО «КФУ им. В.И. Вернадского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Budgetary Institution of Healthcare "Prof. V. K. Krasavitov Clinical Hospital for Veterans of Wars</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>05</day><month>05</month><year>2018</year></pub-date><volume>25</volume><issue>2</issue><fpage>108</fpage><lpage>114</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Михайличенко В.Ю., Иващенко А.С., Самарин С.А., Волик С.А., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Михайличенко В.Ю., Иващенко А.С., Самарин С.А., Волик С.А.</copyright-holder><copyright-holder xml:lang="en">Mykhaylichenko V.Y., Ivashchenko A.S., Samarin S.A., Volik S.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://ksma.elpub.ru/jour/article/view/1139">https://ksma.elpub.ru/jour/article/view/1139</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить эффективность применения анти-VEGF терапии при лечении окклюзий вен сетчатки.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование было включено 124 пациента в возрасте от 23 до 66 лет, в среднем 54,3±8,9 лет, которые находились на амбулаторном и стационарном лечении в офтальмологическом отделении ИНВХ им. В.К. Гусака с 2011 по 2016 года. Нами было сформировано две группы. В группу сравнения вошли 66 пациентов, которые получали стандартную терапию в виде местной антикоагулянтной и противоотечной терапии, дезагрегантов. Для улучшения микроциркуляции и с противоотечной целью назначали внутривенно реополиглюкин, с антигипоксичской целью назначали внутримышечные инъекции актовегина. При отеке макулы и развитии новообразованных сосудов – лазеркоагуляция, интравитреальное или субтеноновое введение тримационолона. В основную группу вошли 58 пациентов, которым, помимо стандартной терапии, вводили препарат Эйлия (афлиберцепт) интравитреально по 2 мг в 0,05 мл. Лечение раствором афлиберцепта для интравитреальных инъекций начинали с одной инъекции 1 раз в месяц в течение последующих пяти месяцев, с дальнейшим переходом на одну инъекцию один раз в два месяца, при этом в период между инъекциями мониторинг не требовался.</p></sec><sec><title>Результаты</title><p>Результаты. При возникновении посттромботической неоваскулярной глаукомы концентрация TGFα в слезной жидкости возрастала в 1,7, а TGFβ – в 28 раз. При окклюзии ветви центральной вены сетчатки по ишемическому типу отмечается снижение систолической и диастолической скорости кровотока в сетчатке. При когерентной оптической томографии с функцией ангиографии при поступлении в обеих группах отмечался достоверный макулярный отек, зоны неперфузии сетчатки, снижение плотности капиллярной сети во внутренних слоях сетчатки на ангио-ОКТ, у 3 пациентов на ангио-ОКТ визуализировались новообразованные сосуды в зоне неперфузии </p></sec><sec><title>Заключение</title><p>Заключение. В группе с применением антиангиогенных препаратов отмечалось более раннее восстановление полей зрения и снижение неоангиогенеза.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. The main aim of our research is to study the effectiveness of anti-VEGF therapy in the treatment of retinal vein occlusions.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study included 124 patients aged between 23 to 66, an average of 54.3±8.9 years old who were on an outpatient and inpatient treatment in the ophthalmologic department of the V.K. Gusak Institute of Emergency and Reconstructive Surgery from 2011 to 2016. We have formed two groups. The comparison group included 66 patients who received standard therapy in the form of local anticoagulant and anti-edematous therapy, disaggregants. To improve microcirculation and with a decongestant purpose, rheopolyglucin was administered intravenously, and intramuscular injections of actovegin were prescribed with an antihypoxic purpose. With edema of the macula and the development of newly formed vessels – laser coagulation, intravitreal or subtenon introduction of trimacionolone. The main group included 58 patients who, in addition to standard therapy, were given the drug Eilia (aflibercept) intravitreally 2 mg in 0.05 ml. Treatment with aflibercept for intravitreal injections started with one injection once a month for the next five months, with a further transition to one injection every two months, with no monitoring required between the injections.</p></sec><sec><title>Results</title><p>Results. When post-thrombotic neovascular glaucoma occurred, the concentration of TGFα in the lacrimal fluid increased by 1.7, and TGFβ by 28-fold. When the branch of the central vein of the retina is occluded according to the ischemic type, the systolic and diastolic blood flow velocity in the retina decreases. With coherent optical tomography with the function of angiography, admission in both groups showed significant macular edema, non-perfusion zones of the retina, a decrease in the density of the capillary network in the inner layers of the retina in angio-OCT, and 3 patients with angio-OCT visualized newly formed vessels in the nonperfusion zone.</p></sec><sec><title>Conclusion</title><p>Conclusion. In the group with the use of anti-angiogenic drugs, earlier restoration of the visual fields and reduction of neoangiogenesis were noted.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>окклюзия вен сетчатки</kwd><kwd>антиангиогенная терапия</kwd><kwd>неоангиогенез</kwd></kwd-group><kwd-group xml:lang="en"><kwd>retinal vein occlusion</kwd><kwd>anti-angiogenic therapy</kwd><kwd>neoangiogenesis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Rogers S., McIntosh R.L., Cheung N. et al. The prevalence of retinal vein occlusion: poolled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;. 117(2), P. 313-319.</mixed-citation><mixed-citation xml:lang="en">Rogers S., McIntosh R.L., Cheung N. et al. The prevalence of retinal vein occlusion: poolled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;. 117(2), P. 313-319.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Захаров В.Д., Каштан О.В., Соломин В.А., Осокин И.Г. Среднесрочные результаты хирургического лечения исходов тромбозов центральной вены сетчатки на основе малоинвазивной (25G) витрэктомии с эндолазерным индуцированием хориоретинальных венозных анастомозов. Вестник Оренбургского государственного университета. 2011; 14(133): 148-150</mixed-citation><mixed-citation xml:lang="en">Zakharov V.D., Kashtan O.V., Solomin V.A., Osokin I.G. Mediumterm results of surgical treatment of outcomes of central retinal vein thrombosis based on minimally invasive (25G) vitrectomy with endolaser induction of chorioretinal venous anastomoses. Bulletin of Orenburg State University. 2011; 14(133): 148-150. (In Russ., English abstract).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Борискина Л.Н., Потапова В.Н., Мелихова И.А., Полякова В.Р. Интравитреальное введение Луцентиса в сочетании с лазеркоагуляцией сетчатки в лечении макулярного отека вследствии тромбоза ветви центральной вены сетчатки. Вестник Тамбовского университета. Серия: Естественные и технические науки. 2014; 19(4): 1092-1093.</mixed-citation><mixed-citation xml:lang="en">Boriskina L.N., Potapova V.N., Melikhova I.A., Polyakova V.R. Intravitreal administration of Lucentis in combination with laser coagulation of the retina in the treatment of macular edema due to thrombosis of the branch of the central vein of the retina. Bulletin of Tambov University. Series: Natural and technical sciences. 2014; 19(4): 1092-1093. (In Russ., English abstract).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Аветисова С.Э., Егорова Е.А., Мошетовой Л.К., Нероева В.В., Тахчиди Х.П. Национальное руководство по офтальмологии. М.; 2008. 599-609.</mixed-citation><mixed-citation xml:lang="en">Avetisova S.E., Egorova EA, Moshetova LK, Neroeva VV, Takhchidi Kh.P. Natsionalnoe rukovodstvo po oftalmologii [National guidelines on ophthalmology]. Moscow: 2008. 599-609 p. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Branch Vein Occlusion Study Group. Argon laser phothocoagulation for macular edema in branch vein occlusion. Am. J. Ophthalmology. 1994; 98: 271-282.</mixed-citation><mixed-citation xml:lang="en">Branch Vein Occlusion Study Group. Argon laser phothocoagulation for macular edema in branch vein occlusion. Am. J. Ophthalmology. 1994; 98: 271-282.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Green W.R., Chan C.C., Hutchins G.M., Terry J.M. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc. 1981; 79: 371-422.</mixed-citation><mixed-citation xml:lang="en">Green W.R., Chan C.C., Hutchins G.M., Terry J.M. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc. 1981; 79: 371-422.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf S, Wolf-Schnurrbusch U. Spectral-domain optical coherence tomography use in macular diseases: a review. Ophthalmologica. 2010; 224: 333-340.</mixed-citation><mixed-citation xml:lang="en">Wolf S, Wolf-Schnurrbusch U. Spectral-domain optical coherence tomography use in macular diseases: a review. Ophthalmologica. 2010; 224: 333-340.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X., Kirby M., Zhao F. Motion analysis and removal in intensity variation based OCT angiography. Biomed Opt Express. 2014; 5: 3833-3847.</mixed-citation><mixed-citation xml:lang="en">Liu X., Kirby M., Zhao F. Motion analysis and removal in intensity variation based OCT angiography. Biomed Opt Express. 2014; 5: 3833-3847.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rodolfo M., Luca D. A., Silvio D. S., et al. Optical Coherence Tomography Angiography in Retinal Vascular Diseases and Choroidal Neovascularization. Journal of Ophthalmology. 2015, Article ID 343515, 8 pages. DOI:10.1155/2015/343515.</mixed-citation><mixed-citation xml:lang="en">Rodolfo M., Luca D. A., Silvio D. S., et al. Optical Coherence Tomography Angiography in Retinal Vascular Diseases and Choroidal Neovascularization. Journal of Ophthalmology. 2015, Article ID 343515, 8 pages. DOI:10.1155/2015/343515.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Захаров В.Д., Каштан О.В., Осокин И.Г. Лазерное и хирургическое лечение исходов тромбозов ретинальных вен. Современные технологии в медицине. 2012; 1: 101-107.</mixed-citation><mixed-citation xml:lang="en">Zakharov V.D., Kashtan O.V., Osokin I.G. Laser and surgical treatment of outcomes of thrombosis of retinal veins. Modern technologies in medicine. 2012; 1: 101-107. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ip M.S., Gottlieb J.L., Kahana A. et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch of Ophthalmol. 2004; 122: 1131-1136.</mixed-citation><mixed-citation xml:lang="en">Ip M.S., Gottlieb J.L., Kahana A. et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch of Ophthalmol. 2004; 122: 1131-1136.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Batioglu F., Ozmert E., Akmese E. Two-year results of intravitreal triamcinolone acetonide injection for the treatment of macular edema due to central retinal vein occlusion. Ann Ophthalmol. 2007; 39(4): 307-311.</mixed-citation><mixed-citation xml:lang="en">Batioglu F., Ozmert E., Akmese E. Two-year results of intravitreal triamcinolone acetonide injection for the treatment of macular edema due to central retinal vein occlusion. Ann Ophthalmol. 2007; 39(4): 307-311.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ramchandran R.S., Fekrat S., Stinnett S.S., Jaffe G.J. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol. 2008; 146: 285-291.</mixed-citation><mixed-citation xml:lang="en">Ramchandran R.S., Fekrat S., Stinnett S.S., Jaffe G.J. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol. 2008; 146: 285-291.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mykhaylichenko V.Yu., Kubyshkin A.V., Fomochkina I.I., Anisimova L.V., Samarin S.A. Experimental induction of reparative morphogenesis and adaptive reserves in the ischemic myocardium using multipotent mesenchymal bone marrow-derived stem cells. Pathophysiology. 2016; 23(2): 95-104. DOI:10.1016/j.pathophys.2016.04.002</mixed-citation><mixed-citation xml:lang="en">Mykhaylichenko V.Yu., Kubyshkin A.V., Fomochkina I.I., Anisimova L.V., Samarin S.A. Experimental induction of reparative morphogenesis and adaptive reserves in the ischemic myocardium using multipotent mesenchymal bone marrow-derived stem cells. Pathophysiology. 2016; 23(2): 95-104. DOI:10.1016/j.pathophys.2016.04.002</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Михайличенко В.Ю., Иващенко А.С. Патофизиологические факторы прогнозирования течения тромбоза вен сетчатки глаза. Таврический медико-биологический вестник.2014; 2(66): 94-98</mixed-citation><mixed-citation xml:lang="en">Mykhaylichenko V.Yu. Ivashchenko A.S. Pathophysiological factors predicting the course of venous thrombosis of the retina of the eye. Taurian medical and biological bulletin. 2014; 2(66): 94-98. (In Russ., English abstract).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Михайличенко В.Ю., Иващенко А.С., Чурилов А.В., Иванцова Н.Л. Клиническое основание применения антиангиогенной терапии при тромбозе вен сетчатки глаза у человека.Таврический медико-биологический вестник. 2014; 4: 65-69.</mixed-citation><mixed-citation xml:lang="en">Mykhaylichenko V.Yu., Ivashchenko A.S., Churilov A.V., Ivantsova N.L. Clinical basis for the use of anti-angiogenic therapy for thrombosis of the retina of the eye in humans. Taurian medical and biological bulletin, 2014; 4: 65-69. (In Russ., English abstract).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Rouvas A., Petron P., Ntouraki A. et al. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion – induced macular edema: nine-month results of prospective study. Retina. 2010; 30(6): 893-902.</mixed-citation><mixed-citation xml:lang="en">Rouvas A., Petron P., Ntouraki A. et al. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion – induced macular edema: nine-month results of prospective study. Retina. 2010; 30(6): 893-902.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
